CheckMate 214: nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma
Dual immunotherapy with nivolumab and ipilimumab lengthened survival compared with sunitinib in intermediate- and poor-risk advanced kidney cancer, with about one in ten patients achieving a complete response that has proved durable over years.
Overview
Phase 3 trial of 1,096 patients with untreated advanced clear cell renal cell carcinoma randomised to nivolumab plus ipilimumab (four doses) followed by nivolumab, or sunitinib, with co-primary endpoints in intermediate- and poor-risk patients.
In intermediate and poor risk, 18-month overall survival was 75 versus 60 percent (hazard ratio 0.63), response 42 versus 27 percent and complete response 9 versus 1 percent; favourable-risk patients had higher response to sunitinib at first analysis. Long-term follow-up shows sustained survival benefit.
- Intermediate and poor risk: 18-month overall survival 75 percent vs 60 percent; hazard ratio 0.63.
- Complete response 9 percent vs 1 percent.
Nivolumab-ipilimumab is a first-line standard for intermediate- and poor-risk clear cell kidney cancer, notable for durable complete responses and treatment-free intervals.
- Favourable-risk patients showed no clear benefit.
- Immune-related adverse events requiring high-dose steroids in about a third.
Similar pages
not linked directly; found by shared links- TermSarcomatoid differentiation (RCC)
Shares CheckMate 214, Ipilimumab, Nivolumab.
- TrialCARMENA
Shares Clear cell renal cell carcinoma, Sunitinib.
- Key paperKEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma
Shares Clear cell renal cell carcinoma, Sunitinib, New England Journal of Medicine.
- Key paperCheckMate 238: adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Shares Ipilimumab, New England Journal of Medicine, Nivolumab.
- Key paperSunitinib malate for the treatment of pancreatic neuroendocrine tumours
Shares Sunitinib, New England Journal of Medicine.
- TrialA Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance
Shares Clear cell renal cell carcinoma, Nivolumab.
- TrialCheckMate 025
Shares Clear cell renal cell carcinoma, Nivolumab.
- PersonLaurence Albiges
Shares CheckMate 214, Ipilimumab, Nivolumab.